CYBIN INC.
HELPNasdaq
$7.25
↑ +3.0%Jul 17 close · end-of-day
Price
1Y↓ -6.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders. It has also developed EMBARK, a psychedelic-assisted psychotherapy.
- CEO
- Douglas L. Drysdale
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- Ontario
- Website
- cybin.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 17, 2026
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.